<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Kidney transplantation in children: Immunosuppression</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Kidney transplantation in children: Immunosuppression</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Kidney transplantation in children: Immunosuppression</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ruth A McDonald, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Niaudet, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H35218094"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The major advance allowing prolonged allograft survival in pediatric kidney transplantation has been the use of immunosuppressive drugs that downregulate the immune response. Although data from adult kidney transplantation trials are used to help guide management decisions in pediatric patients, immunosuppression must often be modified because of the unique clinical effects of some of these agents in children, including their impact on growth and development.</p><p>An overview of immunosuppression regimens used in children undergoing kidney transplantation will be reviewed here. Additional issues concerning transplantation in children, as well as detailed discussions of immunosuppressive issues in kidney transplantation common to both children and adults, are presented separately.(See  <a class="medical medical_review" href="/d/html/6120.html" rel="external">"Kidney transplantation in children: General principles"</a> and  <a class="medical medical_review" href="/d/html/6135.html" rel="external">"Kidney transplantation in children: Outcomes"</a> and  <a class="medical medical_review" href="/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy"</a> and  <a class="medical medical_review" href="/d/html/7353.html" rel="external">"Kidney transplantation in adults: Induction immunosuppressive therapy"</a>.)</p><p class="headingAnchor" id="H2175234"><span class="h1">GOAL AND COMPONENTS OF IMMUNOSUPPRESSIVE THERAPY</span></p><p class="headingAnchor" id="H2989030185"><span class="h2">Goal</span><span class="headingEndMark"> — </span>The goal of immunosuppression is to prevent allograft rejection while minimizing drug side effects such as infection, nephrotoxicity, malignancy, and adverse cosmetic effects.</p><p>Immunosuppressive drug regimens are modified as the risk of acute rejection and allograft loss varies to optimize allograft and patient survival and reduce drug adverse effects.</p><p class="headingAnchor" id="H1934629622"><span class="h2">Components</span><span class="headingEndMark"> — </span>Immunosuppressive regimens for children who undergo kidney transplantation are divided into three categories based on the risk of acute rejection:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Induction therapy</strong> – Induction therapy is used at the time of kidney transplant to reduce the risk of allograft rejection. Most induction strategies mitigate T cell activation and use either interleukin 2 (IL-2) receptor antagonists or T cell-depleting agents in combination with conventional agents. Risk of acute rejection is lower when induction therapy precedes the start of maintenance immunosuppressive therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance therapy</strong> – Maintenance therapy is typically started following induction therapy in the first days following transplantation. The intensity of maintenance immunosuppressive therapy is typically reduced after the perioperative period as the risk of acute rejection decreases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute rejection therapy</strong> – Immunosuppressive therapy is increased to treat acute rejection.</p><p></p><p class="headingAnchor" id="H1338735857"><span class="h2">Patient risk stratification</span><span class="headingEndMark"> — </span>Immunosuppression strategies vary based on a patient's underlying immunologic risk for acute rejection and graft loss. In general, more intensive immunosuppression, particularly T cell-depleting induction therapy, is selected for patients who are at greater risk for allograft rejection (defined as high risk). Risk factors for acute rejection include one or more of the following (see  <a class="medical medical_review" href="/d/html/7353.html" rel="external">"Kidney transplantation in adults: Induction immunosuppressive therapy", section on 'Assessment of immunologic risk'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>One or more human leukocyte antigen mismatches (see  <a class="medical medical_review" href="/d/html/7355.html" rel="external">"Kidney transplantation in adults: HLA matching and outcomes"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Panel reactive antibody greater than 0 percent (sensitization)</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of a donor-specific antibody</p><p class="bulletIndent1"><span class="glyph">●</span>Blood group incompatibility</p><p class="bulletIndent1"><span class="glyph">●</span>Retransplant</p><p class="bulletIndent1"><span class="glyph">●</span>Delayed onset of graft function</p><p class="bulletIndent1"><span class="glyph">●</span>Cold ischemia time greater than 24 hours</p><p class="bulletIndent1"><span class="glyph">●</span>In the United States, Black individuals [<a href="#rid1">1</a>]</p><p></p><p class="headingAnchor" id="H826562521"><span class="h1">OUR APPROACH</span><span class="headingEndMark"> — </span>The optimal immunosuppressive regimen for children who undergo kidney transplantation remains unclear, and there are a wide range of approaches using multiple immunosuppressive agents. Many pediatric transplant centers rely on patient risk stratification to choose induction therapy and then titrate maintenance therapy to avoid excessive immunosuppression. For acute rejection, specific allograft pathologic changes guide the selection of more intensive immunosuppression.</p><p>Our immunosuppressive regimen, which minimizes glucocorticoids, consists of induction therapy that uses a biologic agent (<a class="drug drug_pediatric" data-topicid="13168" href="/d/drug information/13168.html" rel="external">rabbit antithymocyte globulin</a> [rATG]-thymoglobulin) with <a class="drug drug_pediatric" data-topicid="12601" href="/d/drug information/12601.html" rel="external">methylprednisolone</a>, as well as maintenance combination immunosuppression therapy with a calcineurin inhibitor (CNI; <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a>) and an antimetabolite (<a class="drug drug_pediatric" data-topicid="12624" href="/d/drug information/12624.html" rel="external">mycophenolate</a> mofetil [MMF]) [<a href="#rid2">2,3</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Induction therapy</strong> – At our center, we administer rATG-thymoglobulin rather than antithymocyte globulin (ATGAM), <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a>, or interleukin 2 (IL-2) receptor antibodies (eg, <a class="drug drug_pediatric" data-topicid="12842" href="/d/drug information/12842.html" rel="external">basiliximab</a>). (See <a class="local">'Data comparing different agents'</a> below.) [<a href="#rid4">4,5</a>].</p><p></p><p class="bulletIndent1">Intraoperative – For all patients, the first dose of rATG-thymoglobulin is provided intraoperatively at an intravenous (IV) dose of 1.5 mg/kg, preceded with administration of IV <a class="drug drug_pediatric" data-topicid="12601" href="/d/drug information/12601.html" rel="external">methylprednisolone</a> given at a dose of 10 mg/kg (maximum dose of 1 g) [<a href="#rid4">4,5</a>].</p><p></p><p class="bulletIndent1">Postoperative – Further postoperative induction therapy is based on patient risk stratification:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Low-risk profile (first transplant, zero donor-specific antibody, no risk of recurrent disease)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>rATG-thymoglobulin – rATG-thymoglobulin is administered for an additional two doses (three total doses of thymoglobulin, with a cumulative dose of 4.5 mg/kg).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Glucocorticoid minimization – No further glucocorticoid is administered.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High-risk profile (risk factors for acute rejection, as discussed above (see <a class="local">'Patient risk stratification'</a> above))</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>rATG-thymoglobulin – rATG-thymoglobulin is administered for an additional four doses (five total doses of thymoglobulin, with a cumulative dose of 7.5mg/kg).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Glucocorticoid therapy – On postoperative day 1, IV <a class="drug drug_pediatric" data-topicid="12601" href="/d/drug information/12601.html" rel="external">methylprednisolone</a> (dose 10 mg/kg, maximum dose 1 g) or oral <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> (dose of 1 mg/kg given twice a day, maximum dose 40 mg) is administered. Prednisone is then provided or continued and gradually tapered to 0.1 mg/kg daily by six months post-transplant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance immunosuppression</strong> – At our center, maintenance immunosuppression includes enteral MMF and <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a>. (See <a class="local">'Maintenance immunosuppressive agents'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MMF</strong> is started in the operating room at a daily dose of 1200 mg/m<sup>2</sup> and quickly reduced to 900 mg/m<sup>2</sup>/day until postoperative day 14, when the dose is further decreased to 600 mg/m<sup>2</sup>/day. Dosing is modified to target mycophenolic acid levels (MPA) trough levels between 2 and 4 mcg/mL and are reduced further if there is evidence of bone marrow suppression (ie, leukopenia). Enteric-coated <a class="drug drug_pediatric" data-topicid="12624" href="/d/drug information/12624.html" rel="external">mycophenolate</a> sodium (EC-MPS) is used in cases of gastrointestinal intolerance to MMF. <a class="local">'Preferred antimetabolite agent: Mycophenolate'</a> below</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">Tacrolimus</a> – Initial administration and dosing of enteral tacrolimus is based on donor source.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Living donor recipients</strong> – <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">Tacrolimus</a> therapy is started on preoperative day 2 at a dose of 0.025 mg/kg/dose given twice a day. On postoperative day 1, the dose is increased to 0.15 mg/kg/day, divided twice a day (0.075 mg/kg per dose). Of note, other centers do not start tacrolimus prior to transplantation but begin therapy post-transplantation, similar to the protocol we use for deceased donor recipients.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Deceased donor recipients</strong> – On postoperative day 1, <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a> is provided at a daily dose of 0.15 mg/kg/day, divided twice a day (0.075 mg/kg per dose).</p><p></p><p class="bulletIndent3">The dose is adjusted to obtain a 12-hour trough blood level of 10 to 15 ng/mL during the first month post-transplantation. The target trough level is lowered progressively over time. For patients who are rejection free at one-year post-transplant, the trough level is maintained at 3 to 5 ng/mL. (See <a class="local">'Calcineurin inhibitors'</a> below.)</p><p></p><p class="bulletIndent1">Immunosuppression is decreased if there are signs or symptoms of excessive immunosuppression (eg, leucopenia or problematic viral or other infections) or increased if the patient develops acute rejection or subclinical rejection based on surveillance biopsies.</p><p></p><p class="bulletIndent1">We do not routinely use a mammalian (mechanistic) target of rapamycin (mTOR) inhibitor as part of an initial maintenance immunosuppression regimen. Initial use of mTOR is avoided due to effects on wound healing. Subsequent use of mTOR as maintenance immunosuppression is uncommon; however, we use an mTOR inhibitor as an alternative agent in patients who cannot continue taking a CNI due to toxicity, who develop a new cancer after transplantation, or who are noncompliant with therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute rejection therapy</strong> – Acute rejection is diagnosed by biopsy with staging based on Banff criteria for acute cell-mediated and/or antibody-mediated rejection (ABMR)  (<a class="graphic graphic_table graphicRef103469" href="/d/graphic/103469.html" rel="external">table 1</a>). While empiric therapy with glucocorticoids may be indicated if a biopsy cannot be performed in a timely manner, it is discouraged to avoid unnecessary glucocorticoid exposure.</p><p></p><p class="bulletIndent1">Our treatment approach for acute rejection depends on the specific pathologic changes found in the allograft, as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute T cell-mediated rejection (TCMR). (See <a class="local">'Acute T cell-mediated rejection'</a> below.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Banff grade I – A three-day course of IV <a class="drug drug_pediatric" data-topicid="12601" href="/d/drug information/12601.html" rel="external">methylprednisolone</a> (10 mg/kg/day, maximum dose 1 g) is administered, followed by <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> 1 mg/kg (maximum dose 40 mg) twice a day for three days, followed by a two-week oral taper back to the prerejection dose. Other centers also administer rATG-thymoglobulin (dose 1.5 mg/kg) for three days for Banff grade 1B rejection.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Banff grade II or higher or glucocorticoid-resistant rejection – rATG-thymoglobulin (dose 1.5 mg/kg) is administered for 5 to 10 days, in addition to the glucocorticoid regimen used in Banff grade I. The number of doses depends on the severity of TCMR and initial response to therapy. (See <a class="local">'Response to therapy'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antibody-mediated acute rejection – A three- to five-day course of plasma exchange is administered, followed by a single dose of intravenous <a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">immune globulin</a> (IVIG; 2 g/kg). <a class="drug drug_pediatric" data-topicid="12971" href="/d/drug information/12971.html" rel="external">Rituximab</a> (375 mg/m<sup>2</sup>) is then also given weekly for up to four doses. The number of doses depends on the severity of rejection and initial response to therapy. (See <a class="local">'Antibody-mediated rejection'</a> below and <a class="local">'Response to therapy'</a> below.)</p><p></p><p class="headingAnchor" id="H2406018458"><span class="h1">INDUCTION IMMUNOSUPPRESSIVE AGENTS</span><span class="headingEndMark"> — </span>Induction therapy is used to prevent T cell activation and is administered during the perioperative period, when the risk of acute rejection is highest. It generally includes the use of antibodies directed against T cell antigens, in combination with the initiation of maintenance immunosuppression using nonbiologic agents.</p><p>In adults, a large number of controlled randomized trials and meta-analyses indicate that induction therapy consisting of biologic antibodies plus conventional immunosuppressive therapy (eg, glucocorticoids, antimetabolites, and/or calcineurin inhibitor [CNI]) is superior to conventional agent therapy alone in reducing kidney allograft rejection and failure. In children, data are limited on the optimal induction therapy that prevents allograft rejection and failure while minimizing serious adverse effects (eg, infections and malignancies). As a result, the optimal induction therapy agent for children remains unclear and the choice often depends on center preference.</p><p class="headingAnchor" id="H2578853237"><span class="h2">Antibody induction therapy</span><span class="headingEndMark"> — </span>Antibody induction agents include specific antilymphocyte or interleukin 2 (IL-2) receptor antibodies (ie, antagonist) that target T cells.</p><p>The efficacy of antibody induction therapy is supported by a meta-analysis of randomized trials demonstrating that it reduces kidney allograft rejection and allograft failure compared with conventional (ie, nonbiologic) immunosuppressive therapy alone [<a href="#rid6">6</a>]. While these clinical trials enrolled mostly adult patients, several trials included patients as young as 10 years old. In addition, three pediatric trials evaluated antibody induction therapy (OKT3 in one trial, <a class="drug drug_pediatric" data-topicid="12842" href="/d/drug information/12842.html" rel="external">basiliximab</a> in two trials), but they were underpowered to detect a difference in allograft outcomes [<a href="#rid7">7-9</a>]. Retrospective studies in pediatric kidney transplant recipients suggest that prophylactic anti-T cell antibody therapy added to conventional immunosuppressive therapy has a beneficial effect on allograft survival [<a href="#rid10">10</a>].</p><p>Data supporting antibody induction therapy in adult kidney transplant recipients are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/7353.html" rel="external">"Kidney transplantation in adults: Induction immunosuppressive therapy", section on 'Indications for induction therapy'</a>.)</p><p class="headingAnchor" id="H3647144617"><span class="h3">Choice of agent</span><span class="headingEndMark"> — </span>There are fewer data guiding antibody induction agent selection in children receiving a kidney transplant, and induction regimens tend to be center- or patient-specific.</p><p>In our center, we suggest <a class="drug drug_pediatric" data-topicid="13168" href="/d/drug information/13168.html" rel="external">rabbit antithymocyte globulin</a> (rATG)-thymoglobulin rather than other antibody therapy in most patients, but we adjust the number of doses based on patient risk, whereas other centers may use an IL-2 receptor antagonist for induction in a low-risk recipient but use antilymphocyte antibody therapy in a highly sensitized patient or a patient who had a previous failed transplant. (See <a class="local">'Our approach'</a> above and <a class="local">'Data comparing different agents'</a> below.)</p><p>Antibody therapy includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antilymphocyte antibodies</strong> – Antilymphocyte antibodies to T cells block lymphocyte functions by the direct killing of bound T lymphocytes. These agents are used to reverse and prevent acute rejection episodes [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Polyclonal preparations consist of antisera raised in animals (eg, horse, rabbit) immunized with human lymphocytes, thymocytes, or lymphoblasts. They contain a wide variety of antibodies directed against many hematopoietic antigens, including cluster determinant (CD) 2, CD3, CD4, CD8, CD18, and human leukocyte antigen molecules. The two available polyclonal lymphocyte-depleting antibodies are antithymocyte globulin (ATGAM), a polyclonal horse-derived antilymphocyte globulin, and rATG-thymoglobulin (Thymoglobulin), a polyclonal rabbit-derived antilymphocyte globulin.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monoclonal antibodies include OKT3 (Muronab-CD3, Orthoclone), which is no longer used, because there is no clear benefit of OKT3 compared with other antilymphocyte antibody preparations and it has significant adverse effects [<a href="#rid9">9,12-14</a>], and <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a>, a humanized anti-CD52 antibody [<a href="#rid15">15-22</a>], used as induction in some pediatric kidney transplant centers. (See  <a class="medical medical_review" href="/d/html/7353.html" rel="external">"Kidney transplantation in adults: Induction immunosuppressive therapy", section on 'Alemtuzumab'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IL-2 receptor antagonists</strong> – Full T cell activation leads to the calcineurin-mediated stimulation of the transcription, translation, and secretion of IL-2, which induces T cell proliferation. Thus, abrogation of IL-2 activity via the administration of anti-IL-2 receptor antibodies would be an attractive potential therapeutic option for the prevention of acute rejection. The only IL-2 receptor antibody available is <a class="drug drug_pediatric" data-topicid="12842" href="/d/drug information/12842.html" rel="external">basiliximab</a> (Simulect), a chimeric human/mouse monoclonal antibody to the alpha chain of the IL-2 receptor.</p><p></p><p class="headingAnchor" id="H494932215"><span class="h3">Data comparing different agents</span><span class="headingEndMark"> — </span>Although evidence that compares different antibody induction therapy is limited, we use rATG-thymoglobulin for all pediatric kidney transplant recipients based on data from adult and pediatric studies, as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Lower rates of acute rejection with rATG-thymoglobulin compared with other antibody therapy:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>rATG-thymoglobulin versus ATGAM</strong> – In a single-center historic cohort study of pediatric kidney transplant recipients, rATG was associated with a lower acute rejection rates compared with ATGAM [<a href="#rid4">4</a>]. A clinical trial in adults also demonstrated lower acute rejection rates and improved allograft survival in patients who received rATG-thymoglobulin compared with those treated with ATGAM.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>rATG-thymoglobulin versus IL-2 receptor antibodies</strong> (<a class="drug drug_pediatric" data-topicid="12842" href="/d/drug information/12842.html" rel="external">basiliximab</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In adult trials, for patients with a high risk of rejection, rATG-thymoglobulin was more effective compared with <a class="drug drug_pediatric" data-topicid="12842" href="/d/drug information/12842.html" rel="external">basiliximab</a> in preventing acute rejection and, at five-year follow-up, graft loss and mortality. (See  <a class="medical medical_review" href="/d/html/7353.html" rel="external">"Kidney transplantation in adults: Induction immunosuppressive therapy", section on 'Patients at high risk of rejection'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Indirect pediatric data from two large randomized clinical trials reported that the addition of <a class="drug drug_pediatric" data-topicid="12842" href="/d/drug information/12842.html" rel="external">basiliximab</a> to conventional nonantibody induction therapy (eg, standard-dose <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a>, glucocorticoids, and <a class="drug drug_pediatric" data-topicid="12624" href="/d/drug information/12624.html" rel="external">mycophenolate</a> mofetil [MMF] [<a href="#rid8">8</a>] or standard-dose <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a>, glucocorticoids, and <a class="drug drug_pediatric" data-topicid="12923" href="/d/drug information/12923.html" rel="external">azathioprine</a> [<a href="#rid7">7,23</a>]) did not improve clinical outcome in children who underwent kidney transplantation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Scientific Registry of Transplant Recipients data</strong> regarding induction therapy – Analyses of data on all pediatric kidney transplants in the United States between 2000 and 2018 compared induction with <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a>, ATGAM, and IL-2RA agents with primary outcomes of graft and patient survival and risk of rejection at six months.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For children undergoing living donor transplant, long-term graft or patient survival were not affected by the choice of induction agent (<a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a> n = 289, anti-thymocyte n = 1197, and IL-2RA n = 1625) [<a href="#rid24">24</a>]. However, children receiving alemtuzumab induction did have higher acute rejection rates in the first year after transplant and children receiving ATGAM had a higher risk of post-transplant lymphoproliferative disease [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For children undergoing deceased donor transplant who received maintenance immunosuppression of <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a> and <a class="drug drug_pediatric" data-topicid="12624" href="/d/drug information/12624.html" rel="external">mycophenolate</a>, the choice of induction therapy (<a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a> n = 320, r-ATG n = 2091, and IL-2RA n = 2165) did not affect the risk of rejection at 6 or 12 months and did not affect graft and patient survival rates [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>rATG-thymoglobulin and glucocorticoid minimization</strong>; no effect on rate of acute rejection – In two observational pediatric studies, rATG-thymoglobulin induction with glucocorticoid minimization resulted in rejection rates comparable with historic glucocorticoid-based therapy [<a href="#rid2">2,3</a>]. In a third study, thymoglobulin induction and glucocorticoid minimization resulted in stable graft function, favorable linear growth, and no significant infectious complications [<a href="#rid5">5</a>].</p><p></p><p class="headingAnchor" id="H86243149"><span class="h2">Nonbiologic agents</span><span class="headingEndMark"> — </span>Nonbiologic agents are generally started at maintenance doses in combination with antibody induction therapy at the time of transplantation. These include antimetabolites (<a class="drug drug_pediatric" data-topicid="12624" href="/d/drug information/12624.html" rel="external">mycophenolate</a> and, less frequently, <a class="drug drug_pediatric" data-topicid="12923" href="/d/drug information/12923.html" rel="external">azathioprine</a>) and CNIs (<a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a> and, less frequently, <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a>) [<a href="#rid12">12</a>]. Glucocorticoid therapy was commonly used in the past for maintenance immunosuppression in pediatric kidney transplant recipients but is now infrequently used due to significant adverse effects. (See <a class="local">'Maintenance immunosuppressive agents'</a> below.)</p><p class="headingAnchor" id="H35218143"><span class="h1">MAINTENANCE IMMUNOSUPPRESSIVE AGENTS</span></p><p class="headingAnchor" id="H3522945058"><span class="h2">General principles</span></p><p class="headingAnchor" id="H3525029109"><span class="h3">Glucocorticoid-sparing regimen</span><span class="headingEndMark"> — </span>Glucocorticoids were the mainstay of immunosuppressive therapy in the early days of pediatric kidney transplantation. However, the development of newer immunosuppressive agents has greatly reduced the need for glucocorticoid therapy in children undergoing kidney transplantation, thereby avoiding the significant side effects of glucocorticoid therapy. In our center, glucocorticoids are used in low-risk patients only in the setting of premedication for <a class="drug drug_pediatric" data-topicid="13168" href="/d/drug information/13168.html" rel="external">rabbit antithymocyte globulin</a> (rATG)-thymoglobulin during induction therapy. For high-risk patients, glucocorticoids are used in the perioperative period (first six months following transplantation). (See <a class="local">'Our approach'</a> above.)</p><p>Glucocorticoids have multiple side effects in children, including growth impairment, susceptibility to infections, Cushingoid appearance, acne, hypertension, aseptic bone necrosis, cataracts, hyperglycemia, poor wound healing, and psychological effects. The negative impact that glucocorticoids have on appearance may play a role in poor adherence, especially in the body image-conscious adolescent [<a href="#rid26">26</a>].</p><p>Based on the available data, the approach of using a glucocorticoid-sparing protocol in pediatric kidney transplant does not appear to increase the risk of rejection or worsen graft survival [<a href="#rid27">27-32</a>]. However, the optimal approach remains uncertain as other centers continue to use glucocorticoid therapy through the first year following kidney transplantation.</p><p>There are concerns that glucocorticoid withdrawal may be associated with an increased risk of graft loss due to recurrent disease; however, one study reported no difference in graft survival due to recurrent disease in children (4 to 18 years of age) treated with a rapid prednisone-discontinuation protocol compared with historical controls who received glucocorticoid therapy [<a href="#rid32">32</a>]. Nevertheless, more data are needed to ensure that there is not an untoward increased risk of recurrent disease with glucocorticoid withdrawal. In particular, the effect of glucocorticoid withdrawal on recurrence may vary depending on the primary disease.</p><p class="headingAnchor" id="H2540241907"><span class="h3">Combination therapy</span><span class="headingEndMark"> — </span>Maintenance immunosuppression regimens generally consist of a combination of agents with different mechanisms of action, such as antimetabolites (eg, <a class="drug drug_pediatric" data-topicid="12624" href="/d/drug information/12624.html" rel="external">mycophenolate</a> or, less frequently, <a class="drug drug_pediatric" data-topicid="12923" href="/d/drug information/12923.html" rel="external">azathioprine</a>) and calcineurin inhibitors (CNIs; eg, <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a> or, less frequently, <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a>) [<a href="#rid12">12</a>]. Combination therapy provides a synergistic immunosuppressive effect while minimizing the side effects of each individual agent. In our center, a double-agent regimen that includes mycophenolate and tacrolimus is used for maintenance immunosuppression. (See <a class="local">'Preferred antimetabolite agent: Mycophenolate'</a> below.)</p><p class="headingAnchor" id="H1273905984"><span class="h3">Transplant expertise</span><span class="headingEndMark"> — </span>Drug therapy should be managed by a transplant specialist with expertise in balancing the maintenance of excellent allograft function and survival and minimization of the adverse effects of therapy, monitoring therapeutic drug dosing and potential drug interactions  (<a class="graphic graphic_table graphicRef110436" href="/d/graphic/110436.html" rel="external">table 2</a>).</p><p>In addition, extended follow-up is needed to determine whether there are increases in the incidence of post-transplant lymphoproliferative disease and accelerated chronic allograft nephropathy, particularly with the advent of glucocorticoid-sparing regimens.</p><p class="headingAnchor" id="H35218164"><span class="h2">Preferred antimetabolite agent: Mycophenolate</span><span class="headingEndMark"> — </span>Antimetabolic agents interfere with the synthesis of nucleic acids and inhibit the proliferation of both T and B lymphocytes. Although more expensive, <a class="drug drug_pediatric" data-topicid="12624" href="/d/drug information/12624.html" rel="external">mycophenolate</a> mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS) is the preferred antimetabolite over <a class="drug drug_pediatric" data-topicid="12923" href="/d/drug information/12923.html" rel="external">azathioprine</a> because of the reduction of acute rejection and fewer side effects (eg, bone marrow toxicity). In the United States, azathioprine is used less often in maintenance therapy for pediatric kidney transplant patients [<a href="#rid12">12</a>], although it has a role when there is severe gastrointestinal toxicity related to MMF or EC-MPS or in cases where once-daily dosing of immunosuppression is desirable due to adherence issues. In our center, MMF is used in combination with <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a> as maintenance immunosuppression.</p><p>This approach is supported by the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy of </strong><a class="drug drug_pediatric" data-topicid="12624" href="/d/drug information/12624.html" rel="external">mycophenolate</a><strong> versus </strong><a class="drug drug_pediatric" data-topicid="12923" href="/d/drug information/12923.html" rel="external">azathioprine</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Observational data in children report that MMF in combination with <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a> and glucocorticoid therapy had better allograft survival compared with historical controls treated with <a class="drug drug_pediatric" data-topicid="12923" href="/d/drug information/12923.html" rel="external">azathioprine</a> [<a href="#rid33">33,34</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a multicenter study of children treated with MMF, <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a>, and glucocorticoids, the three-year patient and allograft survival rates were 98 and 95 percent, respectively [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In addition, data from adult trials have shown that MMF compared with <a class="drug drug_pediatric" data-topicid="12923" href="/d/drug information/12923.html" rel="external">azathioprine</a> is associated with lower rates of acute rejection and, possibly, improved graft survival. (See  <a class="medical medical_review" href="/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy", section on 'Mycophenolate'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – MMF was developed as a replacement for <a class="drug drug_pediatric" data-topicid="12923" href="/d/drug information/12923.html" rel="external">azathioprine</a> for maintenance immunosuppression and as rescue therapy in patients with rejection episodes refractory to OKT3 [<a href="#rid36">36-38</a>]. It has less bone marrow toxicity compared with azathioprine. Although leukopenia is the most serious adverse effect of azathioprine, pancreatitis, hepatoxicity, neoplasia, and, most notably, skin cancer are rare but serious adverse events. (See  <a class="medical medical_review" href="/d/html/7994.html" rel="external">"Pharmacology and side effects of azathioprine when used in rheumatic diseases"</a> and  <a class="medical medical_review" href="/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy", section on 'Mycophenolate'</a>.)</p><p></p><p class="headingAnchor" id="H1206071352"><span class="h3">Mycophenolate: Dosing, monitoring, and target levels</span><span class="headingEndMark"> — </span>In our center, enteral MMF is started at a daily dose of 1200 mg/m<sup>2</sup>, then decreased to 900 mg/m<sup>2</sup>/day until postoperative day 14, when the dose is further decreased to 600 mg/m<sup>2</sup>/day. We monitor mycophenolic acid levels (MPA) levels using a trough level 12 hours after administration, with targeted levels between 2 and 4 mcg/mL. MPA monitoring avoids both underdosing, which prevents rejection [<a href="#rid39">39-42</a>], and overdosing, which increases the risk of adverse reactions [<a href="#rid39">39,41-43</a>]. In addition, we use monitoring levels as a measure of adherence to the immunosuppression plan.</p><p class="headingAnchor" id="H35218194"><span class="h3">Mycophenolate: Adverse effects</span><span class="headingEndMark"> — </span>Side effects of MMF are dose related. They include diarrhea, vomiting, leukopenia, anemia, and infectious complications. Compared with adults and older children, there is a higher incidence of adverse effects with MMF observed in children below the age of six years that may result in drug discontinuation [<a href="#rid44">44-46</a>].  <a class="medical medical_review" href="/d/html/7356.html" rel="external">Kidney transplantation in adults: Maintenance immunosuppressive therapy, section on 'Mycophenolate'</a></p><p>EC-MPS, an enteric-coated formulation of <a class="drug drug_pediatric" data-topicid="12624" href="/d/drug information/12624.html" rel="external">mycophenolate</a>, was developed to try to improve the upper gastrointestinal tolerability of mycophenolate. Some adult studies and small pediatric case series reported that EC-MPS produced fewer gastrointestinal side effects [<a href="#rid47">47,48</a>]. However, EC-MPS cannot be crushed or made into a suspension, forcing practitioners to only use this in patients who can swallow pills whole. In addition, data on target MPA predose levels or algorithms for the calculation of MPA-AUC<sub>0-12</sub> values generated from MMF-treated patients cannot be applied to patients treated with EC-MPS, because the slow-release galenics of this preparation lead to a more variable pharmacokinetic profile.</p><p class="headingAnchor" id="H35218201"><span class="h2">Calcineurin inhibitors</span><span class="headingEndMark"> — </span>CNIs have been mainstays of immunosuppression for pediatric transplantation for the past several decades and likely account for the continuing improvement in graft survival rates [<a href="#rid49">49-51</a>]. CNIs selectively inhibit calcineurin, thereby impairing the transcription of interleukin 2 (IL-2) and several other cytokines in T cells. By inhibiting cytokine gene transcription, CNIs suppress T cell and T cell-dependent B cell activation.</p><p>Although the choice between the two CNIs, <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a> and <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a>, is based on center preference, tacrolimus is our preferred agent because of the increase in adverse cosmetic effects associated with cyclosporine and the decreased rate of acute rejection seen with tacrolimus [<a href="#rid12">12</a>].  <a class="medical medical_review" href="/d/html/7356.html" rel="external">Kidney transplantation in adults: Maintenance immunosuppressive therapy, section on 'Calcineurin inhibitors'</a></p><p class="headingAnchor" id="H1263497129"><span class="h3">Comparison between tacrolimus and cyclosporine</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">Tacrolimus</a> is the preferred CNI over <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a> because data suggest that tacrolimus is associated with lower rate of acute rejection and better graft survival and lower risk of cosmetic adverse effects.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The efficacy of <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a> relative to <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a> in pediatric kidney transplant recipients is supported by observational data and a single randomized trial, suggesting that tacrolimus reduces the rate of acute rejection and may improve graft survival [<a href="#rid52">52-55</a>].</p><p></p><p class="bulletIndent1">In an open multicenter trial of 196 pediatric kidney transplant recipients, acute rejection rates at one-year follow-up were lower in the <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a> group compared with the <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a> group (37 versus 59 percent) and graft survival at four-year follow-up was improved in the tacrolimus versus cyclosporine group (86 versus 69 percent) [<a href="#rid55">55</a>]. Patient survival was similar at four-year follow-up (94 versus 92 percent).</p><p></p><p class="bulletIndent1">The efficacy of <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a> relative to <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a> is also supported by randomized trials in adult kidney transplant recipients. These data are discussed separately and are based on trials that reported a lower incidence of acute rejection and comparable or superior graft survival with tacrolimus compared with cyclosporine.  <a class="medical medical_review" href="/d/html/7356.html" rel="external">Kidney transplantation in adults: Maintenance immunosuppressive therapy, section on 'Calcineurin inhibitors'</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The toxicity profiles of <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a> and <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a> are similar. Side effects of both CNIs include nephrotoxicity, hypertension, diabetes mellitus (which is more common with tacrolimus), neurotoxicity, hyperkalemia, hypomagnesemia, dyslipidemia, and increased susceptibility to serious infection and risk of malignancy. However, gingival hyperplasia and hirsutism are seen with cyclosporine therapy but <strong>not</strong> with tacrolimus. The adverse cosmetic effects of cyclosporine may contribute to nonadherence to medications, especially in adolescent patients [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus", section on 'Side effects'</a>.)</p><p></p><p class="headingAnchor" id="H1413973524"><span class="h3">Dosing and drug target level</span></p><p class="headingAnchor" id="H3742731078"><span class="h4">Tacrolimus</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The initial oral or nasogastric dose for <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a> is 0.2 to 0.3 mg/kg/day administered in two divided doses [<a href="#rid57">57</a>]. In some cases, tacrolimus is initially administered intravenously (IV) at a dose of 0.05 to 0.1 mg/kg over 24 hours and switched to oral medication within two to three days post-transplant. Dosing is adjusted based on maintaining target levels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug target level</strong> – Target levels for <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a> are generally higher in the early post-transplant period and then are reduced. Target levels vary by center and specific protocol used. In our center, target trough whole blood levels are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>10 to 15 ng/mL during the first month</p><p class="bulletIndent2"><span class="glyph">•</span>5 to 10 ng/mL for subsequent months</p><p class="bulletIndent2"><span class="glyph">•</span>If patients are rejection free at one-year post-transplant, our target trough whole blood levels are further reduced to a range between 3 and 5 ng/mL</p><p></p><p class="headingAnchor" id="H2518954426"><span class="h4">Cyclosporine</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">Cyclosporine</a> doses are higher than those prescribed in adults because the drug appears to have a more rapid metabolism in children [<a href="#rid58">58</a>]. The recommended starting oral dose of cyclosporine is age dependent:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children younger than six years – The starting dose is 500 mg/m<sup>2</sup>/day divided every eight hours.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children older than six years, for patients on combination therapy with glucocorticoids and/or purine synthesis inhibitors – The starting dose is between 12 and 15 mg/kg/day divided every 12 hours.</p><p></p><p class="bulletIndent1">Three to six months post-transplant, dosing is reduced to 4 to 6 mg/kg/day and is adjusted based on trough drug levels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug target level</strong> – Target trough whole blood levels are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>150 and 300 mcg/L for the first three to six months post-transplant</p><p class="bulletIndent2"><span class="glyph">•</span>75 to 125 mcg/L for subsequent months</p><p></p><p class="headingAnchor" id="H3181996336"><span class="h3">Drug interactions with calcineurin inhibitors</span><span class="headingEndMark"> — </span>An important consideration for patients who receive CNIs is that several drugs may interfere with CNI metabolism. A brief review of the drugs is presented elsewhere, and additional information on drug interactions can be found in the <a class="external" href="/drug-interactions">drug interactions program</a> provided by UpToDate. (See  <a class="medical medical_review" href="/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy", section on 'Drug interactions'</a>.)</p><p class="headingAnchor" id="H35218222"><span class="h2">Modification of maintenance therapy</span><span class="headingEndMark"> — </span>Maintenance immunosuppression may be modified in the following settings:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>ABO-incompatible transplant</strong> – Cases of successful ABO-incompatible kidney transplants using desensitization strategies in children have been reported, similar to those reported in adults [<a href="#rid59">59,60</a>]. Desensitization protocols are used to lower the immunogenicity of the incompatibility and involve a combination of <a class="drug drug_pediatric" data-topicid="12971" href="/d/drug information/12971.html" rel="external">rituximab</a>, plasmapheresis, and intravenous <a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">immune globulin</a> (IVIG) to deplete B cell and reduce circulating anti-A/B antibody. (See  <a class="medical medical_review" href="/d/html/113661.html" rel="external">"Kidney transplantation in adults: ABO-incompatible transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intolerance or toxicity of CNIs</strong> – For patients who are unable to tolerate CNIs due to nephrotoxicity or other adverse effects, alternative immunosuppression regimens include use of mammalian (mechanistic) target of rapamycin (mTOR) inhibitors (<a class="drug drug_pediatric" data-topicid="17063" href="/d/drug information/17063.html" rel="external">everolimus</a> or <a class="drug drug_pediatric" data-topicid="12761" href="/d/drug information/12761.html" rel="external">sirolimus</a>) [<a href="#rid61">61,62</a>]. (See  <a class="medical medical_review" href="/d/html/7329.html" rel="external">"Pharmacology of mammalian (mechanistic) target of rapamycin (mTOR) inhibitors"</a> and  <a class="medical medical_review" href="/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy", section on 'Calcineurin inhibitor-related toxicity'</a>.)</p><p></p><p class="headingAnchor" id="H2644295801"><span class="h1">ACUTE REJECTION IMMUNOSUPPRESSION</span><span class="headingEndMark"> — </span>There have been no controlled trials of treatment of acute organ transplant rejection in children. The two principal histologic forms of acute rejection include acute T cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR) and are treated with different regimens. Management of these two conditions in children are based on adult data.</p><p class="headingAnchor" id="H914443155"><span class="h2">Acute T cell-mediated rejection</span><span class="headingEndMark"> — </span>TCMR is caused by T cells that react to donor histocompatibility antigens present within tubules, interstitium, vessels, and glomeruli of the allograft. The histologic changes noted on kidney biopsy that occur with acute TCMR include interstitial infiltration with mononuclear cells and, occasionally, eosinophils and disruption of the tubular basement membranes by the infiltrating cells (ie, tubulitis)  (<a class="graphic graphic_picture graphicRef116699" href="/d/graphic/116699.html" rel="external">picture 1</a>). (See  <a class="medical medical_review" href="/d/html/7352.html" rel="external">"Kidney transplantation in adults: Clinical features and diagnosis of acute kidney allograft rejection", section on 'Acute T cell-mediated (cellular) rejection'</a>.)</p><p>Management is guided predominately by the Banff histologic classification of acute TCMR  (<a class="graphic graphic_table graphicRef103469" href="/d/graphic/103469.html" rel="external">table 1</a>), based on data from adult studies (see  <a class="medical medical_review" href="/d/html/7358.html" rel="external">"Kidney transplantation in adults: Treatment of acute T cell-mediated (cellular) rejection"</a>). The Banff grades are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Borderline – Mild interstitial inflammation (&lt;25 percent of nonsclerotic cortical parenchyma; i0 or i1) plus any tubulitis (t1, t2, or t3) <strong>or</strong> significant interstitial inflammation (&gt;25 percent of nonsclerotic cortical parenchyma; i2 or i3) plus foci of mild tubulitis (t1).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type IA – Significant interstitial inflammation (&gt;25 percent of nonsclerotic cortical parenchyma; i2 or i3) and foci of moderate tubulitis (t2).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type IB – Significant interstitial inflammation (&gt;25 percent of nonsclerotic cortical parenchyma; i2 or i3) and foci of severe tubulitis (t3).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type IIA – Mild-to-moderate intimal arteritis (v1) with or without interstitial inflammation and tubulitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type IIB – Severe intimal arteritis comprising &gt;25 percent of the luminal area (v2) with or without interstitial inflammation and tubulitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type III – Transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation.</p><p></p><p>In our center, therapy for acute TCMR is guided by the Banff histologic grade, as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with Banff grade I, pulse high-dose glucocorticoids (30 mg/kg, maximum dose 1 g) are provided for three days, followed by a course of oral <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> starting at 1 mg/kg (maximum dose 40 mg) administered twice a day for three days that is then tapered to the prerejection dose over two weeks. Some centers also administer <a class="drug drug_pediatric" data-topicid="13168" href="/d/drug information/13168.html" rel="external">rabbit antithymocyte globulin</a> (rATG)-thymoglobulin for patients with Banff grade IB during the three-day intravenous (IV) steroid pulse.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with Banff grade II or III, rATG-thymoglobulin is administered for 5 to 10 days depending on the severity of rejection, in addition to the glucocorticoid regimen used in Banff grade I.</p><p></p><p class="headingAnchor" id="H181637276"><span class="h2">Antibody-mediated rejection</span><span class="headingEndMark"> — </span>ABMR is thought to be caused by the binding of circulating antibodies to donor alloantigens on graft endothelial cells, which results in inflammation, cell damage, and, ultimately, graft dysfunction. Such antigens most commonly include human leukocyte antigen class I and class II antigens and, in recipients of ABO-incompatible transplants, ABO blood group antigens; other nonmajor histocompatibility complex alloantigens on the endothelium may also be targeted. (See  <a class="medical medical_review" href="/d/html/7352.html" rel="external">"Kidney transplantation in adults: Clinical features and diagnosis of acute kidney allograft rejection", section on 'Active antibody-mediated rejection'</a>.)</p><p>ABMR is treated with a combination of immunosuppressive agents with a goal of removing existing donor-specific antibodies and eradicating the clonal population of B cells or plasma cells that is responsible for their production. Therapeutic interventions include plasma exchange, high-dose intravenous <a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">immune globulin</a> (IVIG), <a class="drug drug_pediatric" data-topicid="12971" href="/d/drug information/12971.html" rel="external">rituximab</a> (anti-CD20 agent), and pulse IV <a class="drug drug_pediatric" data-topicid="12601" href="/d/drug information/12601.html" rel="external">methylprednisolone</a>.</p><p>In our center, a three- to five-day course of plasma exchange is administered, followed by a single dose of <a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">IVIG</a> (2 g/kg) and <a class="drug drug_pediatric" data-topicid="12971" href="/d/drug information/12971.html" rel="external">rituximab</a> (375 mg/m<sup>2</sup>) weekly for four doses. The number of doses depends on the severity of ABMR and response to therapy.</p><p class="headingAnchor" id="H801110304"><span class="h2">Response to therapy</span><span class="headingEndMark"> — </span>After the initiation of antirejection therapy, the plasma creatinine concentration may continue to increase for three to four days. However, if therapy reverses rejection, creatinine levels should decrease after one week. The rejection episode may be completely reversible, with the creatinine level returning to levels similar to those observed prior to the rejection episode. In approximately 40 percent of cases, the serum creatinine remains elevated above baseline, which can be due to either chronic damage or ongoing rejection [<a href="#rid63">63</a>].</p><p>A rejection episode may be considered glucocorticoid resistant if no improvement is observed in the plasma creatinine 7 to 10 days after initiation of glucocorticoid pulse therapy. Glucocorticoid-resistant, severe, or recurrent episodes are treated with lymphocyte-depleting antibodies (eg, rATG-thymoglobulin).</p><p>Reevaluation of maintenance immunosuppression is warranted following a rejection episode. One may consider switching immunosuppressive agents. For example, adjustments may include changing to an alternative calcineurin inhibitor (CNI) or from an antimetabolite (ie, <a class="drug drug_pediatric" data-topicid="12624" href="/d/drug information/12624.html" rel="external">mycophenolate</a> mofetil [MMF] or <a class="drug drug_pediatric" data-topicid="12923" href="/d/drug information/12923.html" rel="external">azathioprine</a>) to mammalian (mechanistic) target of rapamycin (mTOR) inhibitor (eg, <a class="drug drug_pediatric" data-topicid="12761" href="/d/drug information/12761.html" rel="external">sirolimus</a>) to take advantage of the synergism between sirolimus and the CNIs as well as considering glucocorticoid therapy. In addition, assessment of the patient's adherence to the medication regimen is always important.</p><p class="headingAnchor" id="H1814746288"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goal</strong> – The goal of immunosuppression in pediatric kidney transplant recipients is to provide an immunosuppressive regimen that optimizes patient survival and allograft survival by preventing acute rejection, while minimizing toxicities such as infection, nephrotoxicity, malignancy, and adverse cosmetic effects. (See <a class="local">'Goal'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Components</strong> – Immunosuppressive therapy is divided into three components. (See <a class="local">'Goal and components of immunosuppressive therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Induction therapy</strong> – Induction therapy provides the highest degree of immunosuppression and is administered during the perioperative period, when the risk of acute rejection is highest.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Maintenance therapy</strong> – The intensify of maintenance immunosuppressive therapy is less as the risk of acute rejection decreases after the perioperative period. Maintenance therapy is typically started at the time of transplantation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute rejection therapy</strong> – Immunosuppressive therapy is increased to treat acute rejection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient risk stratification</strong> – More intensive immunosuppression (eg, induction therapy) is selected for patients who are at greater risk for allograft rejection (defined as high risk). Risk factors include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One or more human leukocyte antigen mismatches (see  <a class="medical medical_review" href="/d/html/7355.html" rel="external">"Kidney transplantation in adults: HLA matching and outcomes"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Panel reactive antibody greater than 0 percent (sensitization)</p><p class="bulletIndent2"><span class="glyph">•</span>Presence of a donor-specific antibody</p><p class="bulletIndent2"><span class="glyph">•</span>Blood group incompatibility</p><p class="bulletIndent2"><span class="glyph">•</span>Retransplant</p><p class="bulletIndent2"><span class="glyph">•</span>Delayed onset of graft function</p><p class="bulletIndent2"><span class="glyph">•</span>Cold ischemia time greater than 24 hours</p><p class="bulletIndent2"><span class="glyph">•</span>In the United States, Black individuals</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Induction immunosuppression</strong> – For pediatric kidney transplant recipients, we recommend that antibody induction therapy be used in conjunction with conventional immunosuppression (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). This is based on data from clinical trials (largely in high-risk adult kidney transplantation recipients) showing that antibody induction therapy improves allograft survival and reduces the risk of acute rejection. Observational studies in pediatric kidney transplant recipients suggest that antibody induction therapy likely has similar benefits in this population. (See <a class="local">'Antibody induction therapy'</a> above and  <a class="medical medical_review" href="/d/html/7353.html" rel="external">"Kidney transplantation in adults: Induction immunosuppressive therapy", section on 'Indications for induction therapy'</a>.)</p><p></p><p class="bulletIndent1">For most pediatric kidney transplant recipients, we suggest <a class="drug drug_pediatric" data-topicid="13168" href="/d/drug information/13168.html" rel="external">rabbit antithymocyte globulin</a> (rATG)-thymoglobulin as the preferred agent for induction therapy rather than antithymocyte globulin (ATGAM) or interleukin-2 (IL-2) receptor antibodies (eg, <a class="drug drug_pediatric" data-topicid="12842" href="/d/drug information/12842.html" rel="external">basiliximab</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). In observational pediatric studies and clinical trials in adults, rATG-thymoglobulin was associated with lower rates of acute rejection and adverse effects compared with ATGAM or basiliximab. (See <a class="local">'Choice of agent'</a> above and  <a class="medical medical_review" href="/d/html/7353.html" rel="external">"Kidney transplantation in adults: Induction immunosuppressive therapy", section on 'rATG-Thymoglobulin'</a>.)</p><p></p><p class="bulletIndent1">In our center, an initial intravenous (IV) dose of rATG-immunoglobulin (1.5 mg/kg) is administered intraoperatively. Additional doses are administered postoperatively, and the number of doses depends on the patient's risk for acute rejection. (See <a class="local">'Data comparing different agents'</a> above and <a class="local">'Our approach'</a> above and <a class="local">'Patient risk stratification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance immunosuppression</strong> – All children who receive a kidney transplantation require maintenance immunosuppression. Maintenance immunosuppression regimens generally consist of a combination of agents with different mechanisms of action such as antimetabolites (eg, <a class="drug drug_pediatric" data-topicid="12624" href="/d/drug information/12624.html" rel="external">mycophenolate</a> mofetil [MMF] or, less frequently, <a class="drug drug_pediatric" data-topicid="12923" href="/d/drug information/12923.html" rel="external">azathioprine</a>) and calcineurin inhibitors (CNIs; eg, <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a> or, less frequently, <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a>). Combination therapy provides a synergistic immunosuppressive effect while minimizing the side effects of each individual agent. (See <a class="local">'Maintenance immunosuppressive agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most pediatric transplant recipients, we suggest a glucocorticoid-sparing maintenance regimen (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). This minimizes the considerable adverse effects associated with long-term glucocorticoid therapy. The available data suggest that a glucocorticoid-sparing regimen does not affect the risk of acute rejection and graft loss. (See <a class="local">'Glucocorticoid-sparing regimen'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most pediatric kidney transplant recipients, we suggest a maintenance regimen consisting of MMF plus <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a> rather than other agents (eg, <a class="drug drug_pediatric" data-topicid="12923" href="/d/drug information/12923.html" rel="external">azathioprine</a> or <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">cyclosporine</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Compared with azathioprine, MMF is better tolerated and may be associated with lower acute rejection rates. Compared with cyclosporine, tacrolimus is generally better tolerated (in particular, it avoids the adverse cosmetic effects of cyclosporine, which may contribute to nonadherence) and it may be associated with lower acute rejection rates. (See <a class="local">'Preferred antimetabolite agent: Mycophenolate'</a> above and <a class="local">'Calcineurin inhibitors'</a> above and <a class="local">'Modification of maintenance therapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>MMF – Enteral MMF is started at a daily dose of 1200 mg/m<sup>2</sup>, and then it is decreased to 900 mg/m<sup>2</sup>/day until postoperative day 14, when the dose is decreased to 600 mg/m<sup>2</sup>/day and modified based on targeted mycophenolic acid levels (MPA) trough levels between 2 and 4 mcg/mL. (See <a class="local">'Our approach'</a> above and <a class="local">'Mycophenolate: Dosing, monitoring, and target levels'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">Tacrolimus</a> – Enteral tacrolimus is started on postoperative day 1 for deceased donor recipients and preoperatively for living donor recipients. The starting dose is 0.075 mg/kg administered as two divided oral doses. This is a lower dose than used in other centers because its administration overlaps with that of rATG-thymoglobulin for two days. The dose is adjusted to obtain a 12-hour trough blood level of 10 to 15 ng/mL during the first month post-transplantation. The target trough level is lowered progressively over time. For patients who are rejection free at one-year post-transplant, the trough level is maintained at 3 to 5 ng/mL. (See <a class="local">'Our approach'</a> above and <a class="local">'Tacrolimus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute rejection immunosuppression</strong> – Immunosuppression for acute rejection, defined as an acute deterioration in allograft function, is based on the specific histology findings observed on kidney biopsy (see <a class="local">'Acute rejection immunosuppression'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children with acute T cell-mediated rejection (TCMR), management is guided by the Banff histologic classification of acute TCMR. As the severity of TCMR increases, more intensive immunosuppression is administered. (See <a class="local">'Acute T cell-mediated rejection'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with Banff grade I TCMR, we suggest administering pulse high-dose glucocorticoids (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). In our center, a three-day course of IV <a class="drug drug_pediatric" data-topicid="12601" href="/d/drug information/12601.html" rel="external">methylprednisolone</a> (30 mg/kg/day, maximum dose 1 g) is administered, followed by <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> 1 mg/kg (maximum dose 40 mg) twice a day for three days, followed by a two-week oral taper back to the prerejection dose.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with Banff grades II or III, we suggest treatment with rATG-thymoglobulin (1.5 mg/kg), in addition to the glucocorticoid regimen used in Banff grade I (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children with antibody-mediated acute rejection, we suggest combined treatment with plasma exchange plus intravenous <a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">immune globulin</a> (IVIG) and <a class="drug drug_pediatric" data-topicid="12971" href="/d/drug information/12971.html" rel="external">rituximab</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). In our center, a typical regimen consists of a three-day course of plasma exchange, followed by a single dose of IVIG (2 g/kg) and rituximab (375 mg/m<sup>2</sup>) weekly for four doses. (See <a class="local">'Antibody-mediated rejection'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 Suppl 3:S1.</a></li><li><a class="nounderline abstract_t">Chavers BM, Chang YC, Gillingham KJ, Matas A. Pediatric kidney transplantation using a novel protocol of rapid (6-day) discontinuation of prednisone: 2-year results. Transplantation 2009; 88:237.</a></li><li><a class="nounderline abstract_t">Li L, Chaudhuri A, Chen A, et al. Efficacy and safety of thymoglobulin induction as an alternative approach for steroid-free maintenance immunosuppression in pediatric renal transplantation. Transplantation 2010; 90:1516.</a></li><li><a class="nounderline abstract_t">Khositseth S, Matas A, Cook ME, et al. Thymoglobulin versus ATGAM induction therapy in pediatric kidney transplant recipients: a single-center report. Transplantation 2005; 79:958.</a></li><li><a class="nounderline abstract_t">Warejko JK, Hmiel SP. Single-center experience in pediatric renal transplantation using thymoglobulin induction and steroid minimization. Pediatr Transplant 2014; 18:816.</a></li><li><a class="nounderline abstract_t">Hill P, Cross NB, Barnett AN, et al. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients. Cochrane Database Syst Rev 2017; 1:CD004759.</a></li><li><a class="nounderline abstract_t">Grenda R, Watson A, Vondrak K, et al. A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. Am J Transplant 2006; 6:1666.</a></li><li><a class="nounderline abstract_t">Offner G, Toenshoff B, Höcker B, et al. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids. Transplantation 2008; 86:1241.</a></li><li><a class="nounderline abstract_t">Benfield MR, Tejani A, Harmon WE, et al. A randomized multicenter trial of OKT3 mAbs induction compared with intravenous cyclosporine in pediatric renal transplantation. Pediatr Transplant 2005; 9:282.</a></li><li><a class="nounderline abstract_t">Feld LG, Stablein D, Fivush B, et al. Renal transplantation in children from 1987-1996: the 1996 Annual Report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 1997; 1:146.</a></li><li><a class="nounderline abstract_t">Kreis H. Antilymphocyte globulins in kidney transplantation. Kidney Int Suppl 1992; 38:S188.</a></li><li class="breakAll">NAPRTCS 2008 Annual Report. Available at: https://web.emmes.com/study/ped/index.htm (Accessed on July 20, 2010).</li><li><a class="nounderline abstract_t">Seikaly M, Ho PL, Emmett L, Tejani A. The 12th Annual Report of the North American Pediatric Renal Transplant Cooperative Study: renal transplantation from 1987 through 1998. Pediatr Transplant 2001; 5:215.</a></li><li><a class="nounderline abstract_t">Niaudet P, Jean G, Broyer M, Chatenoud L. Anti-OKT3 response following prophylactic treatment in paediatric kidney transplant recipients. Pediatr Nephrol 1993; 7:263.</a></li><li><a class="nounderline abstract_t">Tan HP, Kaczorowski D, Basu A, et al. Steroid-free tacrolimus monotherapy after pretransplantation thymoglobulin or Campath and laparoscopy in living donor renal transplantation. Transplant Proc 2005; 37:4235.</a></li><li><a class="nounderline abstract_t">Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg 2005; 200:505.</a></li><li><a class="nounderline abstract_t">Sung J, Barry JM, Jenkins R, et al. Alemtuzumab induction with tacrolimus monotherapy in 25 pediatric renal transplant recipients. Pediatr Transplant 2013; 17:718.</a></li><li><a class="nounderline abstract_t">Kaabak MM, Babenko NN, Samsonov DV, et al. Alemtuzumab induction in pediatric kidney transplantation. Pediatr Transplant 2013; 17:168.</a></li><li><a class="nounderline abstract_t">Supe-Markovina K, Melquist JJ, Connolly D, et al. Alemtuzumab with corticosteroid minimization for pediatric deceased donor renal transplantation: a seven-yr experience. Pediatr Transplant 2014; 18:363.</a></li><li><a class="nounderline abstract_t">Kim IK, Choi J, Vo AA, et al. Safety and Efficacy of Alemtuzumab Induction in Highly Sensitized Pediatric Renal Transplant Recipients. Transplantation 2017; 101:883.</a></li><li><a class="nounderline abstract_t">Ona ET, Danguilan RA, Africa J, et al. Use of alemtuzumab (Campath-1H) as induction therapy in pediatric kidney transplantation. Transplant Proc 2008; 40:2226.</a></li><li><a class="nounderline abstract_t">De Serres SA, Mfarrej BG, Magee CN, et al. Immune profile of pediatric renal transplant recipients following alemtuzumab induction. J Am Soc Nephrol 2012; 23:174.</a></li><li><a class="nounderline abstract_t">Webb NJ, Prokurat S, Vondrak K, et al. Multicentre prospective randomised trial of tacrolimus, azathioprine and prednisolone with or without basiliximab: two-year follow-up data. Pediatr Nephrol 2009; 24:177.</a></li><li><a class="nounderline abstract_t">Riad S, Jackson S, Chinnakotla S, Verghese P. Primary pediatric live-donor-kidney transplant-recipients' outcomes by immunosuppression induction received in the United States. Pediatr Transplant 2021; 25:e13925.</a></li><li><a class="nounderline abstract_t">Riad S, Jackson S, Chinnakotla S, Verghese P. Primary pediatric deceased-donor kidney transplant recipients outcomes by immunosuppression induction received in the United States. Pediatr Transplant 2021; 25:e13928.</a></li><li><a class="nounderline abstract_t">Korsch BM, Fine RN, Negrete VF. Noncompliance in children with renal transplants. Pediatrics 1978; 61:872.</a></li><li><a class="nounderline abstract_t">Tsampalieros A, Knoll GA, Molnar AO, et al. Corticosteroid Use and Growth After Pediatric Solid Organ Transplantation: A Systematic Review and Meta-Analysis. Transplantation 2017; 101:694.</a></li><li><a class="nounderline abstract_t">Grenda R, Watson A, Trompeter R, et al. A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: the TWIST study. Am J Transplant 2010; 10:828.</a></li><li><a class="nounderline abstract_t">Webb NJ, Douglas SE, Rajai A, et al. Corticosteroid-free Kidney Transplantation Improves Growth: 2-Year Follow-up of the TWIST Randomized Controlled Trial. Transplantation 2015; 99:1178.</a></li><li><a class="nounderline abstract_t">Benfield MR, Bartosh S, Ikle D, et al. A randomized double-blind, placebo controlled trial of steroid withdrawal after pediatric renal transplantation. Am J Transplant 2010; 10:81.</a></li><li><a class="nounderline abstract_t">Höcker B, Weber LT, Feneberg R, et al. Prospective, randomized trial on late steroid withdrawal in pediatric renal transplant recipients under cyclosporine microemulsion and mycophenolate mofetil. Transplantation 2009; 87:934.</a></li><li><a class="nounderline abstract_t">Chavers BM, Rheault MN, Gillingham KJ, Matas AJ. Graft loss due to recurrent disease in pediatric kidney transplant recipients on a rapid prednisone discontinuation protocol. Pediatr Transplant 2012; 16:704.</a></li><li><a class="nounderline abstract_t">Jungraithmayr TC, Wiesmayr S, Staskewitz A, et al. Five-year outcome in pediatric patients with mycophenolate mofetil-based renal transplantation. Transplantation 2007; 83:900.</a></li><li><a class="nounderline abstract_t">Cransberg K, Marlies Cornelissen EA, Davin JC, et al. Improved outcome of pediatric kidney transplantations in the Netherlands -- effect of the introduction of mycophenolate mofetil? Pediatr Transplant 2005; 9:104.</a></li><li><a class="nounderline abstract_t">Höcker B, Weber LT, Bunchman T, et al. Mycophenolate mofetil suspension in pediatric renal transplantation: three-year data from the tricontinental trial. Pediatr Transplant 2005; 9:504.</a></li><li><a class="nounderline abstract_t">Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995; 345:1321.</a></li><li><a class="nounderline abstract_t">Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60:225.</a></li><li><a class="nounderline abstract_t">A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996; 61:1029.</a></li><li><a class="nounderline abstract_t">Borrows R, Chusney G, Loucaidou M, et al. Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. Am J Transplant 2006; 6:121.</a></li><li><a class="nounderline abstract_t">Tredger JM, Brown NW. Mycophenolate: better value through monitoring? Transplantation 2006; 81:507.</a></li><li><a class="nounderline abstract_t">Kuypers DR, Le Meur Y, Cantarovich M, et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 2010; 5:341.</a></li><li><a class="nounderline abstract_t">Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002; 13:759.</a></li><li><a class="nounderline abstract_t">Mourad M, Malaise J, Chaib Eddour D, et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 2001; 47:88.</a></li><li><a class="nounderline abstract_t">Bunchman T, Navarro M, Broyer M, et al. The use of mycophenolate mofetil suspension in pediatric renal allograft recipients. Pediatr Nephrol 2001; 16:978.</a></li><li><a class="nounderline abstract_t">Butani L, Palmer J, Baluarte HJ, Polinsky MS. Adverse effects of mycophenolate mofetil in pediatric renal transplant recipients with presumed chronic rejection. Transplantation 1999; 68:83.</a></li><li><a class="nounderline abstract_t">Höcker B, van Gelder T, Martin-Govantes J, et al. Comparison of MMF efficacy and safety in paediatric vs. adult renal transplantation: subgroup analysis of the randomised, multicentre FDCC trial. Nephrol Dial Transplant 2011; 26:1073.</a></li><li><a class="nounderline abstract_t">Pape L, Ahlenstiel T, Kreuzer M, Ehrich JH. Improved gastrointestinal symptom burden after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in kidney transplanted children. Pediatr Transplant 2008; 12:640.</a></li><li><a class="nounderline abstract_t">Vilalta Casas R, Vila López A, Nieto Rey JL, et al. Mycophenolic Acid reaches therapeutic levels whereas mycophenolate mofetil does not. Transplant Proc 2006; 38:2400.</a></li><li><a class="nounderline abstract_t">Tejani A, Stablein DM, Donaldson L, et al. Steady improvement in short-term graft survival of pediatric renal transplants: the NAPRTCS experience. Clin Transpl 1999; :95.</a></li><li><a class="nounderline abstract_t">Colombani PM, Dunn SP, Harmon WE, et al. Pediatric transplantation. Am J Transplant 2003; 3 Suppl 4:53.</a></li><li><a class="nounderline abstract_t">Tejani A, Ho PL, Emmett L, et al. Reduction in acute rejections decreases chronic rejection graft failure in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Am J Transplant 2002; 2:142.</a></li><li><a class="nounderline abstract_t">McKee M, Segev D, Wise B, et al. Initial experience with FK506 (tacrolimus) in pediatric renal transplant recipients. J Pediatr Surg 1997; 32:688.</a></li><li><a class="nounderline abstract_t">Neu AM, Ho PL, Fine RN, et al. Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study. Pediatr Transplant 2003; 7:217.</a></li><li><a class="nounderline abstract_t">Trompeter R, Filler G, Webb NJ, et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol 2002; 17:141.</a></li><li><a class="nounderline abstract_t">Filler G, Webb NJ, Milford DV, et al. Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporin microemulsion. Pediatr Transplant 2005; 9:498.</a></li><li><a class="nounderline abstract_t">Magee JC, Bucuvalas JC, Farmer DG, et al. Pediatric transplantation. Am J Transplant 2004; 4 Suppl 9:54.</a></li><li><a class="nounderline abstract_t">Shaw LM, Holt DW, Keown P, et al. Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clin Ther 1999; 21:1632.</a></li><li><a class="nounderline abstract_t">Harmon WE, Sullivan EK. Cyclosporine dosing and its relationship to outcome in pediatric renal transplantation. Kidney Int Suppl 1993; 43:S50.</a></li><li><a class="nounderline abstract_t">Nayak AB, Ettenger RB, McGuire S, et al. Optimizing HLA matching in a highly sensitized pediatric patient using ABO-incompatible and paired exchange kidney transplantation. Pediatr Nephrol 2015; 30:855.</a></li><li><a class="nounderline abstract_t">Stojanovic J, Adamusiak A, Kessaris N, et al. Immune Desensitization Allows Pediatric Blood Group Incompatible Kidney Transplantation. Transplantation 2017; 101:1242.</a></li><li><a class="nounderline abstract_t">Harmon W, Meyers K, Ingelfinger J, et al. Safety and efficacy of a calcineurin inhibitor avoidance regimen in pediatric renal transplantation. J Am Soc Nephrol 2006; 17:1735.</a></li><li><a class="nounderline abstract_t">Höcker B, Feneberg R, Köpf S, et al. SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity. Pediatr Transplant 2006; 10:593.</a></li><li><a class="nounderline abstract_t">McDonald R, Ho PL, Stablein DM, et al. Rejection profile of recent pediatric renal transplant recipients compared with historical controls: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Am J Transplant 2001; 1:55.</a></li></ol></div><div id="topicVersionRevision">Topic 6128 Version 49.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19845597" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : KDIGO clinical practice guideline for the care of kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19623020" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pediatric kidney transplantation using a novel protocol of rapid (6-day) discontinuation of prednisone: 2-year results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20935596" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Efficacy and safety of thymoglobulin induction as an alternative approach for steroid-free maintenance immunosuppression in pediatric renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15849550" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Thymoglobulin versus ATGAM induction therapy in pediatric kidney transplant recipients: a single-center report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25311592" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Single-center experience in pediatric renal transplantation using thymoglobulin induction and steroid minimization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28073178" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16827869" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19005406" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15910382" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A randomized multicenter trial of OKT3 mAbs induction compared with intravenous cyclosporine in pediatric renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10084775" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Renal transplantation in children from 1987-1996: the 1996 Annual Report of the North American Pediatric Renal Transplant Cooperative Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1405373" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Antilymphocyte globulins in kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1405373" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Antilymphocyte globulins in kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11422826" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The 12th Annual Report of the North American Pediatric Renal Transplant Cooperative Study: renal transplantation from 1987 through 1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8518095" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Anti-OKT3 response following prophylactic treatment in paediatric kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16387087" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Steroid-free tacrolimus monotherapy after pretransplantation thymoglobulin or Campath and laparoscopy in living donor renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15804464" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24164824" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Alemtuzumab induction with tacrolimus monotherapy in 25 pediatric renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23442101" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Alemtuzumab induction in pediatric kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24712738" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Alemtuzumab with corticosteroid minimization for pediatric deceased donor renal transplantation: a seven-yr experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27495773" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Safety and Efficacy of Alemtuzumab Induction in Highly Sensitized Pediatric Renal Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18790199" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Use of alemtuzumab (Campath-1H) as induction therapy in pediatric kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22052056" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Immune profile of pediatric renal transplant recipients following alemtuzumab induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18688657" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Multicentre prospective randomised trial of tacrolimus, azathioprine and prednisolone with or without basiliximab: two-year follow-up data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33333629" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Primary pediatric live-donor-kidney transplant-recipients' outcomes by immunosuppression induction received in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33314638" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Primary pediatric deceased-donor kidney transplant recipients outcomes by immunosuppression induction received in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/353683" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Noncompliance in children with renal transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27736823" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Corticosteroid Use and Growth After Pediatric Solid Organ Transplantation: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20420639" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: the TWIST study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25539467" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Corticosteroid-free Kidney Transplantation Improves Growth: 2-Year Follow-up of the TWIST Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19663893" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A randomized double-blind, placebo controlled trial of steroid withdrawal after pediatric renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19300199" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prospective, randomized trial on late steroid withdrawal in pediatric renal transplant recipients under cyclosporine microemulsion and mycophenolate mofetil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22574837" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Graft loss due to recurrent disease in pediatric kidney transplant recipients on a rapid prednisone discontinuation protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17460560" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Five-year outcome in pediatric patients with mycophenolate mofetil-based renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15667622" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Improved outcome of pediatric kidney transplantations in the Netherlands -- effect of the introduction of mycophenolate mofetil?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16048604" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Mycophenolate mofetil suspension in pediatric renal transplantation: three-year data from the tricontinental trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7752752" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7645033" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8623181" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16433766" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16495794" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Mycophenolate: better value through monitoring?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20056756" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11856782" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11148182" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11793083" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The use of mycophenolate mofetil suspension in pediatric renal allograft recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10428272" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Adverse effects of mycophenolate mofetil in pediatric renal transplant recipients with presumed chronic rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20670958" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Comparison of MMF efficacy and safety in paediatric vs. adult renal transplantation: subgroup analysis of the randomised, multicentre FDCC trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18798359" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Improved gastrointestinal symptom burden after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in kidney transplanted children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17097947" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Mycophenolic Acid reaches therapeutic levels whereas mycophenolate mofetil does not.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11038628" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Steady improvement in short-term graft survival of pediatric renal transplants: the NAPRTCS experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12694050" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pediatric transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12099516" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Reduction in acute rejections decreases chronic rejection graft failure in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9165452" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Initial experience with FK506 (tacrolimus) in pediatric renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12756047" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11956848" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16048603" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporin microemulsion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15113355" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pediatric transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10566561" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Current opinions on therapeutic drug monitoring of immunosuppressive drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8246370" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Cyclosporine dosing and its relationship to outcome in pediatric renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25750074" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Optimizing HLA matching in a highly sensitized pediatric patient using ABO-incompatible and paired exchange kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27463537" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Immune Desensitization Allows Pediatric Blood Group Incompatible Kidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16687625" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Safety and efficacy of a calcineurin inhibitor avoidance regimen in pediatric renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16856996" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12095039" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Rejection profile of recent pediatric renal transplant recipients compared with historical controls: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS).</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
